Sysmex Corporation · Fiscal year ended March 2026
From counting blood cells to selling reliable test results.
Sysmex's history contains an unusual phrase for an instrument maker. In 1965, founder Taro Nakatani articulated the idea of “selling the results.” A machine alone could not guarantee a reliable laboratory result. The company therefore added reagents, reference materials and academic support around its analyzers. FY2025 net sales reached ¥500.0 billion. The underlying model is not just to sell instruments, but to support the reliability of the result produced by the entire testing process.
This is not investment advice or a stock recommendation. We reorder company-published primary-source facts to make the shape of the business easier to see.
Sysmex began with a machine that automatically counted blood cells.
But the company quickly decided the machine itself was not the whole product.
An analyzer, reagent and reference-material vessels, and a blank booklet for knowledge interpret the wider testing system. Not actual equipment or procedures, measured results or a guarantee of accuracy.
Net sales are ¥500.0bn
Current scale and long-term target
FY2025 actuals and the FY2034 target are different time horizons.
The origin was a push to automate laboratory testing.
Japan’s first automated hematology analyzer in 1963
“Selling the results”
That idea quickly pushed the company beyond hardware.
Academic support began in 1966
Reagents followed in 1967
Quality control became part of the offering in 1968
Japan’s first fully automated system in 1975
Sample feeding became automatic in 1979
The testing fields themselves also widened.
From hematology into urine, coagulation and immunochemistry
Overseas expansion began in 1972
Sell the instrument.
Supply the reagent.
Check the measurement with reference materials.
Provide the knowledge needed to use the system well.
That is what “selling the results” came to mean.
THE VIEW AFTER THE NUMBERS
What the numbers suggest
Sysmex generated ¥500.0 billion of net sales and ¥51.8 billion of operating profit in FY2025.
Its technical origin was Japan’s first automated hematology analyzer in 1963.
But in 1965 the founder articulated the idea of “selling the results.”
Academic support, reagents and quality-control reference materials followed. Sysmex then automated more of the testing workflow and expanded into urinalysis, hemostasis and immunochemistry.
Sysmex did not stop being an instrument company.
It expanded the scope of the product around the instrument, combining hardware, reagents, quality control and knowledge to deliver a reliable laboratory result.
Primary sources used
Why Invest in Sysmex
Sysmex Corporation
Open source →Sysmex's History
Sysmex Corporation
Open source →Sysmex's History (Timeline)
Sysmex Corporation
Open source →